| abstract |
REFERS TO DERIVATIVES OF 2-PHENOXY-6-PHENYL-NICOTINIC ACID AND 2-PHENOXY-6-PYRIDYLNICOTINIC ACID OF FORMULA (I) WHERE R1 IS HALOGEN, CYANE, ALKYL (C1-C4), AMONG OTHERS; R2 IS HALOGEN, CYANE, ALKYL (C1-C6), ALCOXY (C1-C6) AND -NR9-C (= O) -R10 OPTIONALLY SUBSTITUTED, n IS A NUMBER FROM 0 TO 3; A ES N or C-R7; R3 IS HO FLUOR; R4 IS H, F, Cl, CN OR (C1-C4) ALKYL; R5 IS H, HALOGEN, NITRO, CYANE, AMONG OTHERS; R6 AND R7 ARE INDEPENDENTLY H, HALOGEN, NITRO, AMONG OTHERS; R8 IS H, METHYL OR TRIFLUOROMETHYL; R12 IS H O FLUOR. THEY ARE SELECTED: 2- (2-CHLOROPHENOXY) -6- [4- (TRIFLURomethyl) PHENYL] -NICOTINIC ACID, 2- (2-CHLOROPHENOXY) -6- (4-FLUORO-3-METHYLPHENYL) -NICOTINIC ACID, BETWEEN OTHERS. IT ALSO REFERS TO PHARMACEUTICAL COMPOSITIONS AND A PREPARATION PROCEDURE. THESE COMPOUNDS ARE PPAR-ALPHA MODULATORS, BEING USEFUL IN THE TREATMENT OF CARDIOVASCULAR DISEASES, PARTICULARLY DYSLIPIDEMIA, ARTERIOSCLEROSIS AND HEART FAILURE |